Top 10 Nanotech Capital Raises and Investors in the U.S. – October 16^th – November 15^th, 2025

Several interesting transactions closed in the Nanotech sector over the past month. If you would like more info on these deals or would like to discuss the capital raising market for your company, please contact me.

PIPE

1. Cardiol Therapeutics, life sciences company that researches and develops anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases, received $11 million of development capital through a private placement.
2. Nanoviricides, a nano-biopharmaceutical company that discovers, develops, and commercializes therapeutics to advance the care of patients suffering from life-threatening viral infections, received $6 million of development capital through a private placement.
3. Tharimmune, a biotechnology company that develops a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases, received $545 million of development capital through a private placement.
4. Zentek, IP development and commercialization company that focuses on next-gen healthcare solutions in the areas of prevention, detection, and treatment, received $1.77 million of development capital through a private placement.

Later Stage VC

5. xMEMS, a microelectromechanical systems speaker platform that delivers active thermal management for smartphones, SSDs, and data center rack servers, raised $21 million of Series D venture funding in a deal led by Boardman Bay Capital Management.

Early Stage VC

6. 2Pi Optics, metasurface flat optics technology that overcomes fundamental limitations of the traditional optical system, raised $11.74 million of Series A venture funding.

Accelerator/Incubator

7. Brightlight Photonics, integrated photonic devices for compact light generation, received $113,434 of grant funding from Northeast Microelectronics Coalition as a part of its PROPEL Programme.

Angel (individual)

8. Paretor, standardized RNA transfection reagents that simplify and scale RNA delivery for clinical applications, raised $150,000 of angel funding.

Grant

9. Axoft, implantable electronics that amplify brain-machine communication for patients with neurodegenerative conditions, received $835,000 of grant funding from Massachusetts Technology Collaborative.

Seed Round

10. CereCura Nanotherapeutics, next-generation neurological therapeutics that treat brain disease, raised $1 million of seed funding.

#castleplacement #capitalraising #privateequity #venturecapital #investment #nanotech

Jesus Tueme

Managing Director

Please contact me if you have any questions or would like to discuss your capital raise:

Email: jtueme@castleplacement.com

(C) (646) 479-7616

Send us a message:

Sources: Information on this page was derived from a variety of sources including Bloomberg, Company Websites, Crunchbase, PitchBook and other news outlets. Castle Placement® does not warrant or guarantee this information, nor makes any representations as to the accuracy of the information. For more Risks, see CPGO Risks and Disclaimers.